13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001882053
Total reported value
$427.5M
$427.5M
13 檔
42.3%
According to the latest 13F quarterly dataset, Boone Capital Management LLC managed an equity portfolio of $427.5M at the end of Q1 2026, spanning 13 distinct U.S. exchange-listed positions.
Boone Capital Management LLC executed strategic sector rebalancing during Q1 2026, establishing 5 new positions while fully exiting 7 holdings and trimming 2 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 11.92% | -0.54% | — | |
| 2 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 11.51% | -1.87% | +19.79% | |
| 3 | CI | THE Cigna Group | Stock-Healthcare | 11.24% | -0.97% | +42.58% | |
| 4 | MDT | Medtronic plc | Stock-Healthcare | 10.57% | -10.57% | EXIT | |
| 5 | TFX | Teleflex Inc | Stock-Healthcare | 10.22% | +1.27% | — | |
| 6 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 9.48% | -1.67% | +33.02% | |
| 7 | GRDN | Guardian Phrmcy Services-a | Stock-Other | 7.28% | -0.31% | — | |
| 8 | AZN | AstraZeneca PLC | Stock-Healthcare | 6.65% | -6.65% | EXIT | |
| 9 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 6.57% | +2.05% | +28.28% | |
| 10 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 5.21% | +0.71% | +23.72% | |
| 11 | AVNS | Avanos Medical Inc | Stock-Other | 5.09% | -5.09% | EXIT | |
| 12 | KOD | Kodiak Sciences Inc | Stock-Other | 3.29% | +0.15% | -44.16% | |
| 13 | TENX | Tenax Therapeutics Inc | Stock-Other | 0.98% | -0.98% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | CI | THE Cigna Group | +2.9% | +42.58% | Add |
| 2 | BMRN | Biomarin Pharmaceutical Inc | +1.8% | +33.02% | Add |
| 3 | MIRM | Mirum Pharmaceuticals Inc | +1.5% | — | Unchanged |
| 4 | IONS | Ionis Pharmaceuticals Inc | +1.1% | +19.79% | Add |
| 5 | BBIO | Bridgebio Pharma Inc | +0.8% | +23.72% | Add |
| 6 | UNH | Unitedhealth Group Inc | +0.2% | +28.28% | Add |
| 7 | KOD | Kodiak Sciences Inc | -1.1% | -44.16% | Trim |
| 8 | MDT | Medtronic plc | -2.4% | -7.17% | Trim |
| 9 | TFX | Teleflex Inc | — | NEW | New buy |
| 10 | GRDN | Guardian Phrmcy Services-a | — | NEW | New buy |
| 11 | AZN | AstraZeneca PLC | — | NEW | New buy |
| 12 | NBIX | Neurocrine Biosciences Inc | — | EXIT | Sold out |
| 13 | AZNN | Astrazeneca Plc-spons Adr | — | EXIT | Sold out |
| 14 | HQY | Healthequity Inc | — | EXIT | Sold out |
| 15 | LIVN | LivaNova PLC | — | EXIT | Sold out |
| 16 | AVNS | Avanos Medical Inc | — | NEW | New buy |
| 17 | RAPT | Rapt Therapeutics Inc | — | EXIT | Sold out |
| 18 | TYRA | Tyra Biosciences Inc | — | EXIT | Sold out |
| 19 | WVE | Wave Life Sciences Ltd. | — | EXIT | Sold out |
| 20 | TENX | Tenax Therapeutics Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Boone Capital Management LLC reported a total U.S. public equity portfolio value of $427.5M across 13 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including MIRM, IONS, CI) accounted for 42.3% of total reported equity market value during Q1 2026.
Top New Position Initiated
TFX
市值: $33.3M
Top Position Liquidated / Trimmed
NBIX
前期市值: $21.5M
During Q1 2026, Boone Capital Management LLC's top holdings by market value included MIRM (11.9%)、IONS (11.5%)、CI (11.2%). The largest single position, MIRM, represented 11.9% of total portfolio value.
In Q1 2026, Boone Capital Management LLC made 19 total portfolio adjustments, initiating 5 new buys, adding to 5 positions, trimming 2 holdings, and fully liquidating 7 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.